Haemophilus influenzae Type b Vaccine
For more information, see Hib ACIP Vaccine Recommendations.
These vaccines are prepared from the purified capsule of Haemophilus influenzae type b (Hib). All Hib vaccines use polyribosylribitol phosphate (PRP) as the polysaccharide, but 4 different protein carriers are used in the 4 different Hib conjugate vaccines available:
PRP-D and HbOC vaccines are no longer available in the US.
Combination vaccines that contain Hib conjugate vaccine include DTaP-IPV/Hib (Pentacel®), Hib-HepB (COMVAX®), and Hib-MenCY (MenHibrix®).
Some Hib vaccines—PRP-T (ActHIB®, Pentacel®, or MenHibrix®) and PRP-OMP (PedvaxHIB® or COMVAX®)—can be used in infants as young as 6 wk. Another Hib vaccine (Hiberix®) can be used only for the last dose of the Hib schedule in children ≥ 12 mo.
The Hib vaccine is a routine childhood vaccination (see Table: Recommended Immunization Schedule for Ages 0–6 yr).
This vaccine is also recommended for
Adults with anatomic or functional asplenia and those scheduled for elective splenectomy if they are unimmunized (ie, if they have not previously received a primary series plus booster dose or ≥ 1 dose of Hib vaccine after age 14 mo), although some experts suggest giving a dose before elective splenectomy regardless of vaccination history
Immunocompromised adults (eg, because of cancer chemotherapy or HIV infection) if they are unimmunized
People who have had a hematopoietic stem cell transplantation regardless of their vaccination history
Hib vaccine 0.5 mL is given IM. A primary childhood series is given in 3 doses at age 2, 4, and 6 mo or in 2 doses at age 2 and 4 mo, depending on the formulation. In either case, a booster is recommended at age 12 to 15 mo.
One dose is given to older children, adolescents, and adults who have asplenia or who are scheduled for an elective splenectomy if they are unimmunized. Some experts suggest giving a dose before elective splenectomy regardless of vaccination history. The dose is given ≥ 14 days before elective splenectomy if possible.
A 3-dose regimen is given 6 to 12 mo after hematopoietic stem cell transplantation; doses are separated by ≥ 4 wk.